Comparative Pharmacology
Head-to-head clinical analysis: LIPO HEPIN versus LIQUAEMIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPO HEPIN versus LIQUAEMIN SODIUM.
LIPO-HEPIN vs LIQUAEMIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIPO-HEPIN (unfractionated heparin) binds to antithrombin III, accelerating the inactivation of thrombin (factor IIa) and activated factor X (Xa), thereby inhibiting coagulation.
Heparin binds to antithrombin III, accelerating the inactivation of thrombin and factor Xa, thereby inhibiting coagulation cascade.
Initial IV bolus 80 units/kg, then continuous IV infusion 18 units/kg/hr; or subcutaneous 5000 units every 8-12 hours. Dose adjusted based on aPTT.
Initial adult dose: 5,000 units IV bolus, followed by continuous IV infusion at 1,000–2,000 units/hour; or 10,000–20,000 units subcutaneously every 12 hours. Dose adjusted based on aPTT.
None Documented
None Documented
1-2 hours (therapeutic doses); dose-dependent: 30-60 min at low doses, up to 4-6 hours at high doses. Heparin is eliminated by a saturable zero-order process, leading to nonlinear pharmacokinetics. Clinical context: prolonged half-life in renal impairment or hepatic disease.
Mean 1.5 hours (range 1-2 hours) after IV administration; increases with dose (e.g., 25,000 U IV: ~2.5 h). Clinical context: nonlinear pharmacokinetics; half-life prolonged in hepatic or renal impairment.
Renal: 30-60% as unchanged drug; minor biliary/fecal (<10%). Clearance predominantly via hepatic metabolism (desulfation) and reticuloendothelial system uptake.
Primarily renal (heparin is metabolized and excreted as uroheparin and other metabolites; up to 50% of administered dose appears in urine as unchanged heparin, but clearance is dose-dependent and nonlinear).
Category C
Category C
Anticoagulant
Anticoagulant